Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

22.86 -0.13 (-0.57%)

Delayed Quote Updated: 1:40 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nurix Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 Next >

Nurix Therapeutics (NASDAQ:NRIX) Breakout Setup Backed by Technical Rating of 8 and Setup Rating of 9 ↗

September 18, 2026

Via Chartmill

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

July 09, 2026

From Nurix Therapeutics, Inc.

Via GlobeNewswire

Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

June 08, 2026

href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell...

Via Benzinga

Topics Stocks

A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 ↗

May 06, 2026

Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains.

Via The Motley Fool

Topics Regulatory Compliance

Nurix Therapeutics Inc (NASDAQ:NRIX) Reports Mixed Q4 2025 Results, Highlights Key Clinical Milestone ↗

January 28, 2026

Via Chartmill

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip ↗

October 09, 2025

Via Stocktwits

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

April 22, 2026

From Nurix Therapeutics, Inc.

Via GlobeNewswire

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

March 23, 2026

From Nurix Therapeutics, Inc.

Via GlobeNewswire

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

December 24, 2025

Issued on behalf of GT Biopharma, Inc.

From Equity Insider

Via GlobeNewswire

13 Analysts Have This To Say About Nurix Therapeutics ↗

November 04, 2025

Via Benzinga

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...

Via MarketMinute

Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views ↗

October 10, 2025

Via Benzinga

Nurix Therapeutics Posts Downbeat Q3 Results, Joins Orthopediatrics, Levi Strauss And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

October 10, 2025

Via Benzinga

Why Applied Digital Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket ↗

October 10, 2025

Via Benzinga

Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday ↗

October 10, 2025

US stock futures up, Apogee Enterprises, Levi Strauss, VolitionRX, USANA Health Sciences, Nurix Therapeutics report results.

Via Benzinga

NURIX THERAPEUTICS INC (NASDAQ:NRIX) Misses Q3 2025 Estimates, Shares Drop ↗

October 09, 2025

Nurix Therapeutics Q3 2025 results miss revenue and EPS estimates, triggering a stock drop. The biotech firm also announced pivotal trial plans for its lead drug candidate.

Via Chartmill

6 Analysts Assess Nurix Therapeutics: What You Need To Know ↗

July 31, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 17, 2025

Via Benzinga

Which stocks are moving after the closing bell on Thursday? ↗

July 17, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts ↗

July 14, 2025

Via Benzinga

Amazon To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday ↗

July 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 10, 2025

Via Benzinga

Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗

July 10, 2025

Via Benzinga

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments ↗

July 09, 2025

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year.

Via Stocktwits

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.